GNI Group Ltd.
http://www.gnipharma.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From GNI Group Ltd.
Venture Funding Deals: MedImmune Spinout Viela Lands $250m Series A
China's JW Therapeutics nets $90m for cancer cell therapy, including backing from biotechs Celgene and WuXi. Meanwhile, Foghorn sounds out a $50m A round for its gene trafficking technology applications.
China’s HEC Plans Novel IPF Study To Make Splash In US
Tommy Lin, head of Business Development and Global Licensing for HEC Pharma, talks to Scrip’s Brian Yang on how the Chinese domestic drug company is looking to develop its anti-fibrosis drug in the US.
Brazil to secure good hep C prices, but what about other expensive drugs?
The cost of hepatitis C drugs has prompted strong reactions across the world from India to Spain, but not so in Brazil where the government looks close to agreeing a favorable price with the manufacturers. Unfazed by its faltering economy and increasingly unsustainable healthcare system, Brazil's health ministry says it is set to offer free access to Bristol-Myers Squibb's Daklinza (daclatasvir), Gilead's Sovaldi (sofosbuvir) and Janssen's Olysio (simeprevir).
Japan Bioventures SymBio, GNI Spread U.S. Wings
Trying to address some of the expansion challenges faced by their peers, two Japanese bioventures have taken steps to boost their presence and profile in the U.S.
Company Information
- Industry
- Pharmaceuticals
-
Medical Devices
- Biomaterials
-
Biotechnology
- Antisense, Oligonucleotides
-
Drug Discovery Tools
- Bioinformatics
- Genomics-Proteomics